Cambridge Innovation Capital
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
Trent AI launches from stealth with £10m seed round led by LocalGlobe and Cambridge Innovation Capital to provide layered security for AI agents
Trent AI is an agentic security startup that provides a layered security solution for AI agents and autonomous workflows. Its system monitors, assesses and mitigates risks across the lifecycle of agent-based systems to help development and security teams deploy safely.
Semarion secures £2.9m in funding led by Parkwalk to accelerate cell-based drug discovery
Semarion develops cell assay technology that enables adherent cell models to be handled as assay-ready, barcoded reagents. Its platform is used by pharmaceutical and life sciences organisations to improve flexibility, scalability and data generation in drug discovery workflows.
BeyondMath secures a £14m seed round led by Cambridge Innovation Capital to run engineering-grade simulations faster with AI model
BeyondMath develops a physics-based AI model that simulates complex engineering systems. It enables industrial companies to run high-fidelity simulations much faster to improve product design and performance.
HotHouse Therapeutics emerges from stealth with £3m pre-seed led by SynBioVen to develop plant-based drug compounds
HotHouse Therapeutics develops plant-based methods for producing pharmaceutical compounds, using AI and bioengineering to create scalable alternatives to scarce natural ingredients in drug and vaccine supply chains.
InvenireX secures £2m in seed funding led by DSW Ventures to accelerate DNA nanotechology detection
InvenireX develops programmable DNA nanotechnology for ultra-sensitive disease detection, combining nanoscale structures, microfluidics and AI to identify genetic markers far earlier than existing methods.
T-Therapeutics secures £24m Series A extension with Tencent and BGF to develop T cell receptor therapeutics for cancer and autoimmune disease
T-Therapeutics develops next-generation T cell receptor therapies designed to target cancer and autoimmune disease, advancing bispecific molecules that selectively remove disease-driving immune cells while preserving healthy function.
TRIMTECH raises £24m seed led by Cambridge Innovation Capital and SV Health Investors to advance neurodegenerative treatments
TRIMTECH Therapeutics develops targeted protein degradation medicines that selectively remove harmful protein aggregates, focusing on neurodegenerative and inflammatory diseases with limited existing treatment options.
Forefront RF secures £16m to power next-gen connectivity solutions
Forefront RF designs tunable radio frequency components that allow connected devices to support more frequency bands in less space, improving performance and reducing complexity in wearables and mobile electronics.
More venture news
- 7 Apr 2026
Trent AITrent AI launches from stealth with £10m seed round led by LocalGlobe and Cambridge Innovation Capital to provide layered security for AI agents
SeedCybersecurity - 11 Feb 2026
OvermindOvermind raises a £2m seed round led by Osney Capital to secure and improve performance of agentic AI systems
SeedDeveloper Tools - 7 Apr 2026
FermtechFermtech raises a £2.5m seed round led by Elbow Beach to scale production of sustainable cocoa alternative
SeedAgriculture
